Cargando…
The timelines for the price and reimbursement authorization in Italy 2018–2020
OBJECTIVE: This investigation aimed to guarantee the principles of transparency in public administration; to inform citizens about the time to patient access to reimbursed medicines; to assess the duration of the P&R process for the first time in the period 2018–2020; and to evaluate whether and...
Autores principales: | Gallo, Valentina, Alessi, Eva, Montilla, Simona, Altamura, Gianluca, Traversa, Giuseppe, Trotta, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810802/ https://www.ncbi.nlm.nih.gov/pubmed/36619645 http://dx.doi.org/10.3389/fmed.2022.1055359 |
Ejemplares similares
-
Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy
por: Trotta, Francesco, et al.
Publicado: (2019) -
Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018) -
Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983) -
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021) -
Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)